Loading organizations...
Engitix: Biotech company developing therapies using a human ECM drug discovery platform for solid tumors, fibrosis, and inflammation.
Engitix is a London-based biotechnology company that develops therapies targeting the extracellular matrix in solid tumors, fibrosis, and inflammatory diseases using a proprietary human drug discovery platform. The enterprise commercializes organ decellularisation and tissue engineering research originating from University College London to enable preclinical drug discovery for complex oncology and fibrotic conditions. To advance its therapeutic pipeline, Engitix generates revenue and shares resources through strategic development partnerships with major pharmaceutical and artificial intelligence companies, including Dompé, Takeda, and Morphic. Operating from its headquarters at WestWorks in White City Place, the private firm has raised approximately $79 million in total Series A funding, which includes a $25 million extension led by Mike Platt's Netherton Investments, and plans to scale its operations to 80 full-time employees. Engitix was founded in 2016 by Giuseppe Mazza and Massimo Pinzani.
Engitix has raised $85.4M across 3 funding rounds.
Engitix has raised $85.4M in total across 3 funding rounds.
Engitix has raised $85.4M in total across 3 funding rounds.
Engitix's investors include Michael Edward Platt, Gianluca Rossetti.
Engitix has raised $85.4M across 3 funding rounds. Most recently, it raised $25.0M Series A Extension in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 9, 2026 | $25.0M Series A Extension | Michael Edward Platt | |
| Jan 19, 2022 | $54.0M Series A | Gianluca Rossetti, Michael Edward Platt | |
| Nov 27, 2018 | $6.4M Series A |